Archive: Raymond J. March
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth. His research has appeared in Health Economics, Southern Economic Journal, Public Choice, Research Policy, Food Policy, Journal of Institutional Economics, The Independent Review and other academic outlets. His popular articles have appeared in Fortune, Washington Examiner, National Interest, Washington Times, Sun Sentinel, The Hill, Real Clear Health, and Medical News Daily. He earned his Ph.D. from Texas Tech University.
Full Biography and Publications
Full Biography and Publications
The Mental Health Crisis and FDA Hurdles
Despite promising research, the potential for MDMA, and other psychedelic drugs to help treat mental illnesses depends on the a pending FDA decision
Favor Local Action to Combat the Coronavirus
The government’s tendency to take drastic action and achieve lackluster results suggest that local efforts to mitigate crises might be more successful.
Are More Vaping Bans Coming Soon? Let’s Hope Not!
To truly “prioritize children, family, and the public health,” we should consider telling the FDA to stop regulating e-cigarettes cold turkey.
Only Markets Can Alleviate Drug Shortages
The most onerous barriers to alleviating drug shortages are regulations.
New FDA Commissioner, Same FDA Problem
The most beneficial regulations the new FDA commissioner can implement, by far, will be restrictions on the FDA itself.
Telemedicine Continues to Reach New Heights
Thankfully, telemedicine provides solutions for many who might otherwise suffer healthcare-access woes.
Breakthrough Alzheimer’s Drug Puts FDA’s Drug-Approval Process into Question
Peer-reviewed research and many case studies highlight weaknesses in the FDAs drug approval approach.
Is Right-to-Try Legislation a Bust? Time for a Second Opinion.
While right-to-try is currently underused, efforts to expand its role in helping those with terminal illnesses are underway.
Banning E-Cigarette Sales Will Do More Harm than Good
Efforts to ban vaping are extremely unlikely to succeed and may push consumers toward harmful alternatives.
How Government Prolonged the Lobotomy
While the lobotomy offers a cautionary tale of medicine gone astray, it should also provide a cautionary tale of the harmful consequences of state-assisted health policies.
New Study Finds FDA in Contempt of the U.S. Constitution
The vast majority of agency regulations were passed by “low-level officials and employees with no authority to issue rules.”
Worried About Big Pharma? Then Reduce the FDA’s Regulatory Power.
To compete for FDA attention, drug makers now needed a way to navigate new safety hurdles to have their products approved.